Merck gets cancer drug bar as Halozyme wins cross-border European injunction
By Inbar Preiss ( October 9, 2026, 10:51 GMT | Insight) -- A Dutch court has barred Merck’s under-the-skin version of cancer drug Keytruda in eight European countries, upholding Halozyme’s drug-delivery patent and applying EU top court guidance allowing courts to issue cross-border injunctions involving foreign patent rights.US pharmaceutical giant Merck Sharp & Dohme has been barred from manufacturing and marketing an under-the-skin version of its blockbuster cancer drug Keytruda in eight European countries after a Dutch court found that the treatment infringes a Halozyme drug-delivery patent....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.